Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
Schneeweiss A, Lagkadinou E, Wilkinson G, Boix O, Thiele S, Rudolph M, Rentzsch C, Hurvitz S, Ma C, Tsimberidou A, Moulder S, Varga A, Jörger M, Hess D, Ocker M. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers (Basel) 2019; 11
10.12.2019
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy
10.12.2019
Cancers (Basel) 2019; 11
Schneeweiss Andreas, Lagkadinou Eleni, Wilkinson Gary, Boix Oliver, Thiele Silke, Rudolph Marion, Rentzsch Christine, Hurvitz Sara A, Ma Cynthia, Tsimberidou Apostolia M, Moulder Stacy, Varga Andrea, Jörger Markus, Hess Dagmar, Ocker Matthias
Weiter
